Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023 ...

The anti-xerostomia effects of muscarinic agonists (cholinomimetics) are reviewed. Cevimeline (cevimeline monohydrochloride hemihydrate) is a novel muscarinic agonist that stimulates salivary ...

The FDA has approved Karuna/Bristol Myers Squibb’s KarXT (Cobenfy) — an oral dual M1/M4 muscarinic acetylcholine receptor (mAChR) agonist — for schizophrenia. The fixed-dose combination of xanomeline ...

The recent FDA approval of KarXT (Cobenfy), developed by Karuna Therapeutics (a subsidiary of Bristol Myers Squibb), marks a pivotal moment in the treatment of schizophrenia. KarXT, an oral dual M1/M4 ...

Muscarinic acetylcholine receptors (mAChRs) are central to the modulation of neurotransmission in the human brain and are emerging as promising targets in the management of neuropsychiatric disorders.

Trial to study positive, negative, and cognitive domains of Schizophrenia based on ANAVEX®3-71’s ability to synergistically activate both SIGMAR1 and M1 muscarinic receptors NEW YORK, Jan. 16, 2024 ...

Perimenopause was linked with an increased risk of developing mania and major depressive disorder-- but not schizophrenia spectrum disorders -- when compared with the late reproductive period. (Nature ...

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers Squibb’s schizophrenia treatment Cobenfy (KarXT) has had an unusual odyssey ...

AbbVie's acquisition of Cerevel Therapeutics enhances its neuroscience pipeline with promising candidates Emraclidine and Tavapadon, expected to significantly boost revenues post-approval. Emraclidine ...

Neurocrine Biosciences (NBIX) shares tumbled 19% on Wednesday, despite the company announcing that day that its schizophrenia candidate NBI-1117568 (‘568) met its primary endpoint in a Phase II trial, ...

The FDA on Thursday approved xanomeline and trospium chloride (Cobenfy) for schizophrenia in adults, the first new class of drug for the condition in more than 30 years. In contrast to antipsychotics ...